• Adrian Simpson, United States says, "If you are looking for a fair deal on medical supplies, IDM is something I would seriously recommend. Am hooked for life."
  • Craig, United States says, "Seemed easy to purchase, reasonable prices. Good customer service when I used it."
  • Brian Pavey, United States says, "IDM makes online shopping a pleasure. Shopping is so simple that you just breeze through it."
  • Harry Mason, United States says, "I have to admit am a bit of a lazy bloke when it comes to ordering online .And IDM pampers me to the hit as it's so simple to order."
  • John Hanks, United States says, "I was a sceptic until my first order. After, I received my first package, I turned believer. Now, it’s been 3 years since I have been ordering from IDM."
  • Natalie Wallace, United States says, "I was apprehensive about how my doubts would be addressed but what the heck,I went ahead and placed my order. Customer service was patient and helped me out."
  • Mark Penning, United States says, "Happy I got my package just in time for my vacation. Needless to say, it made my holiday a wonderfully satisfying experience."
  • Ask our pharmacist, if you have any questions related to your medications
    Click to find International Shipping charges at our pharmacy.
    Shop & Earn @ InternationalDrugMart
    Easy and secure shopping @ InternationalDrugMart.com.
    Get your instant Coupon now!
    You can find the latest happening of our pharmacy
    Follow us on Twitter

      AstraZeneca's Nasal Flu Vaccine Approved In Europe

      Posted Attradesignalonline.com

      LONDON -(Dow Jones)- AstraZeneca PLC (AZN) Tuesday said its nasal flu vaccine has been approved in Europe for children and adolescents, but is unlikely to go on sale until 2012.

      The vaccine, which is sprayed into the nose rather than given as an injection, was developed by the drug maker's U.S. unit MedImmune and is already on sale for both adults and children in the U.S. where it is known as FluMist.

      Marketing approval in Europe, where it will be called Fluenz, is for the prevention of seasonal influenza in children aged from two to less than 18 years and follows a recommendation by the London-based European Medicines Agency in October.

      "We hope that the availability of this nasal spray influenza vaccine with its novel mechanism of action will help reduce the spread of influenza," said Alex Zukiwski, M.D., executive vice president and chief medical officer of MedImmune, the biologics unit of AstraZeneca.

      The product's approval is based on a review of data from 73 global clinical studies and U.S. post-marketing studies of more than 141,000 people conducted in 38 countries. Study objectives included clinical safety and tolerability, clinical efficacy and effectiveness, and immunogenicity.

      Feb 03, 2011


      Share this Article!

    Back to top^